Resveratrol and Curcumin for Chagas Disease Treatment—A Systematic Review

Abstract

Chagas disease (CD) is a neglected protozoan infection caused by Trypanosoma cruzi, which affects about 7 million people worldwide. There are two available drugs in therapeutics, however, they lack effectiveness for the chronic stage—characterized mainly by cardiac (i.e., cardiomyopathy) and digestive manifestations (i.e., megaesophagus, megacolon). Due to the involvement of the immuno-inflammatory pathways in the disease’s progress, compounds exhibiting antioxidant and anti-inflammatory activity seem to be effective for controlling some clinical manifestations, mainly in the chronic phase. Resveratrol (RVT) and curcumin (CUR) are natural compounds with potent antioxidant and anti-inflammatory properties and their cardioprotective effect have been proposed to have benefits to treat CD. Such effects could decrease or block the progression of the disease’s severity. The purpose of this systematic review is to analyze the effectiveness of RVT and CUR in animal and clinical research for the treatment of CD. The study was performed according to PRISMA guidelines and it was registered on PROSPERO (CDR42021293495). The results did not find any clinical study, and the animal research was analyzed according to the SYRCLES risk of bias tools and ARRIVE 2.0 guidelines. We found 9 eligible reports in this study. We also discuss the potential RVT and CUR derivatives for the treatment of CD as well.

Polyphenols as Potent Epigenetics Agents for Cancer

“…Furthermore, curcumin restored p15INK4b expression by hypomethylating its promoter, resulting in cell cycle arrest in the G1 phase and apoptosis. Curcumin suppressed tumor growth in mice implanted with the MV4-11 cell line of AML [ 124 ]. In a TRAMP mouse model of prostate cancer, curcumin inhibited tumor growth by reverting methylation of the Nrf2 promoter.…”